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The pathophysiology of acute graft-versus-host
disease (aGVHD) is known to involve donor T cells
responding to host histoincompatible allo-antigens
presented by the host antigen presenting cells (APCs)
and the subsequent induction of pro-inflammatory
cytokines and cellular effectors that cause target organ
damage. In a more general sense, GVHD can be
considered as an immune response against foreign
antigens that has gone awry. Similar to all immune
responses, GVHD, can be understood as a process
that consists of (A) triggers, (B) sensors, (C) mediators,
and (D) effectors of GVHD.
Triggers for Induction of GVHD
Like all immune responses, certain triggers are crit-
ical for induction of acute graft-versus-host disease
(aGVHD). These include: (1) Disparities between histo-
compatibility antigens: antigen disparity can be at the level
of major histocompatibility complex (MHC), that is,
MHC mismatched or at the level of minor
histocompatibility antigens (miHA), that is, MHC
matched but miHA mismatched [1]. The severity of
aGVHD is directly related to the degree of MHC mis-
match [2]. In bone marrow transplants (BMT) that are
MHC matched but miHA disparate, donor T cells still
recognize MHC-peptide derived from the products
of recipient polymorphic genes, the miHAs. The
expression of miHAs is wide and variable. Some1Department of Medicine 3312 CCGC, University
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whereas someothers such as theH-Y antigens, are ubiq-
uitously expressed [3]. It is now being increasingly ap-
preciated that the extent of the allo-antigens can
impact the degree of allo-specific T cell responses [4].
(2) Damage induced by conditioning regimens and
underlying diseases: under most circumstances, the initia-
tion of an adaptive immune response is triggered by the
innate immune response. The innate immune system is
triggered by certain exogenous and endogenous mole-
cules.This is likely the case in the induction of aGVHD.
Pattern recognition receptors such as Toll-like recep-
tors (TLR), nucleotide-binding oligomerization do-
main containing 2 (NOD2) [5] play an essential role in
innate immunity and in initiating the cellular signaling
pathways that activate cytokine secretion, such as
NF-kB. Some of their ligands, such as lipopolysaccha-
ride, CpG, and MDP2, which is recognized by TLR-
4, TLR-9, and NOD2, respectively, are released by
the preparative regimens and contribute to the induc-
tion and enhancement of allo-T cell responses [6-10].
In thisway, the conditioning regimens amplify the secre-
tion of proinflammatory cytokines like interleukin (IL)-
1, tumor necrosis factor (TNF)-a [7,11,12], IL-6, and
other interferon family members in a process described
as a ‘‘cytokine storm.’’ In addition to the exogenous
microbial-associated molecules, endogenous noninfec-
tious triggers as a consequence of damage, called
damage-associated molecular patterns (DAMPs) such
as adenosine-50-triphosphate also play a critical role in
GVHD [13,14]. In fact, the proinflammatory cytokines
themselvesmight serve asDAMPs.Other infectious and
sterile stimuli, as yet not reported, might also play a role
in triggering an allo-T cell cells to host antigens.
Sensors of GVHD
The triggers that initiate an immune response have
to be sensed and presented. APCs might be considered
the sensors for aGVHD. The APCs sense the DAMPs,
present the MHC disparate or miHA disparate pro-
tein, and provide the critical secondary (costimulatory)
and tertiary (cytokine) signals for activation of the
alloreactive T cells, the mediators of aGVHD. APCs
sense allo-disparity through MHC and peptide com-
plexes. Dendritic cells (DCs) are the most potent
APCs and the primary sensors of allo-disparity [15].
Recipient DCs that have been primed by theS17
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and peptide complexes to donor T cells at the time
of transplant [16]. In the case of hematopoietic cell
transplants (HCTs), recipient APCs present the en-
dogenous and the exogenous antigens to donor
CD81 and CD41 T cells, respectively. As such, they
are crucial for the induction of donor regulatory T
cell responses and in suppressing GVHD [17]. DCs
are important initiators and regulators of immune re-
sponses. The role of DC subsets in GVHD is just
beginning to be understood. The role of other hema-
topoietic derived APCs, such as Langerhan cells, mac-
rophages, B cells, and basophils has been recently
investigated. In the presence of other hematopoietic-
derived APCs, these APCs either play no role or have
a regulatory effect on the severity of GVHD induction
[18-22]. The role of nonhematopoietic-derived APCs,
in the absence of radiosensitive hematopoietic-derived
APCs, such as endothelial and epithelial cell subsets in
this process sensing and inducing an allo-T cell
response is as yet not well explored. Furthermore,
the kinetics of the switch from recipient to donor
APCs, the contributions of different APCs subsets,
the importance of direct alloantigen presentation,
and the magnitude of indirect alloantigen presentation
in GVHD remains to be largely determined. An
intriguing and potentially novel aspect of the role of
APCs is whether they can be modulated to enhance
the presentation of tumor specific antigens while not
concomitantly enhancing allo-antigen presentation in
order to accentuate graft-versus-tumor effects without
aggravating GVHD.
APCs provide the critical costimulation signals for
turning on the aGVHD process. The interaction
between the MHC/allopeptide complex on APCs
and the T cell receptor of donor T cells along with
the signal via T cell costimulatory molecules and their
ligands on APCs is required to achieve T cell activa-
tion, proliferation, differentiation, and survival and
the in vivo blockade of positive costimulatory mole-
cules (such as CD28, ICOS, CD40, CD30, etc.), or
inhibitory signals (such as PD-1 and CTLA-4)
mitigate or exacerbate aGVHD, respectively [23].Mediators of GVHD
These include primarily the donor T cell subsets.
Evidence suggests that alloreactive donor T cells
consist of several subsets with different stimuli respon-
siveness, activation thresholds, and effector functions.
The allo-antigen composition of the host determines
which donor T cells subsets differentiate and prolifer-
ate. As mentioned previously, in the majority of
HLA-matched HCT, aGVHD may be induced by
either or both CD41 and CD81 subsets responses to
miHAs. The repertoire and immunodominance of
the GVHD-associated peptides presented by MHCclass I and class II molecules has not been defined
[24]. Donor na€ıve CD62L1 T cells are the primary
alloreactive T cells that drive the GVHD reaction
while the donor effector memory CD62L2 T cells
do not [25,26]. Interestingly, donor regulatory T cells
(Tregs) expressing CD62L are also critical to the
regulation of GVHD [27,28]. We now know that it is
possible to modulate the alloreactivity of na€ıve T cells
by inducing anergy with costimulation blockade, dele-
tion via cytokine modulation, or mixed chimerism.
Donor effectormemoryTcells that are nonalloreactive
do not induce GVHD, yet are able to transfer func-
tional memory [25]. In contrast, memory T cells that
are alloreactive can cause severe GVHD [22,29,30].
GVHD is negatively regulated by Tregs. In mouse
BMT models, naturally occurring donor-derived
Tregs suppress the proliferation of conventional
T cells, prevent GVHD, and preserve graft-versus-
leukemia (GVL) effects depending upon the ratio of
effector T cells to Tregs [31-36]. In addition, based
on the dominant cytokines that are produced upon
activation, T cells can be distinguished into various
subsets such as Th1, Th2, and Th17 cells. The Th1
cytokines (interferon [IFN]-g, IL-2 and TNF-a) have
been implicated in the pathophysiology of aGVHD.
IL-2 production by donor T cells remains the main
target ofmany current clinical therapeutic and prophy-
lactic approaches, such as cyclosporine, tacrolimus, and
monoclonal antibodies (mAbs) against the IL-2 and its
receptor to control aGVHD [37,38]. But emerging
data indicate an important role for IL-2 in the genera-
tion and maintenance of CD41CD251 Foxp31Tregs,
suggesting that prolonged interference with IL-2 may
have an unintended consequence in the prevention
of the development of long-term tolerance after alloge-
neic HCT [39-42]. Furthermore, the role of Th1/Th2
and Th17 cytokines is complex and might be model
dependent [43-55]. Moreover, these cells are required
for the GVL effects.Effectors and Amplifiers of GVHD
The effector phase that leads to GVHD target
organ damage is a complex cascade that involves cyto-
lytic cellular effectors such as CD8 cytotoxic T lym-
phocytes (CTLs), CD4 T cells, natural killer cells,
and inflammatory molecules such as IL-1b, TNF-a,
IFN-g, IL-6, and reactive oxygen species [56]. The
cellular effectors require cell-cell contact to kill the
cells of the target tissues via activation of perforin-
granzyme, Fas-FasL (CD95-CD95L), or TNFR-
TRAIL pathways. Other CTLs killing mechanisms
such as TWEAK, and LTb/LIGHT pathways have
also been implicated in GVHD [57-64]. It is important
to note that CTL pathways are essential for GVL
effects as well. Inflammatory pathways, by contrast,
based on animal models, do not require cell-cell
Biol Blood Marrow Transplant 18:S17-S26, 2012 S19Biology of Acute GVHDcontact to kill target cells and are not particularly crit-
ical of GVL.GVHDdamage by the cellular effectors is
amplified by these inflammatory mediators including
IFN-g produced by T cells, TNF-a, and IL-1 pro-
duced by T cells and monocytes/macrophages.
All of the above aspects of the biology of aGVHD
have been summarized in the mold of a normal
immune response. Although this allows for accessing
the biology of GVHD, it is important to note that
GVHD is a complicated systemic process with as yet
still many unknowns and is not a simplified, linear,
or cyclical process.REFERENCES
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TO HUMAN
Gerard Socie, MD, PhD
Much of our understanding of the biology of
GVHD has developed from two preclinical animal
models: the mouse and the dog (reviewed in [1-6]).
Because the inbred mouse model has been used as
the basis for much of our knowledge of the immuno-
logic mechanisms of GVHD, this Perspective will
focus on murine models but also will highlight several
aspects of the canine model where approach. Because
there are significant species differences between
humans andmice, five points are important to consider
when drawing conclusions from studies with animal
models and before correlation to the clinical allogeneic
HSCT scenario.
1. The conditioning regimen used to prepare the recip-
ient: in murine GVHD studies, irradiation alone is
typically used, although regimen intensity ranges
from no conditioning in immune-competent or
immune-deficient recipients to myeloablative doses
of irradiation followed by marrow rescue. Irradia-
tion often is used with large fraction doses and
high dose rates not commonly used in patients.
Typically no chemotherapy is given along with irra-
diation and chemotherapy alone regimens are not
commonly studied in aGVHD models.
2. The immunologic disparity between donor and recipient:
a diverse array of mouse inbred strain combinations
is used, resulting in a variety of MHC- and/or
S22 Biol Blood Marrow Transplant 18:S17-S26, 2012P. Reddy et al.MiHA-disparate models. These different strain
combinations have different Th1/Th2/Th17 as
well as Treg content and can sway the dominance
of CD41 or CD8- T cell effectors in GVHD.
Thus, conclusions in one model may not translate
into other immunologically distinct models or
into the clinic.
3. The source of donor cells: typically spleen cells and/or
lymph node cells are added to the BM graft to pro-
vide a sufficient dose of T cells for the induction of
GVHD in most murine strain combinations, in
contrast to peripheral blood or bone marrow har-
vests used in human studies.
4. The microbial baseline of the animal facility and the
use of prophylactic antibiotics can alter the immu-
nological responses in GVHD and markedly affect
the sensitivity and response to cytoreductive condi-
tioning.Whereas in rodents, mice are housed under
specific-pathogen free conditions since birth,
humans are not. Therefore, extrapolation of murine
data between laboratories may be difficult and clin-
ical translation of such findings into HSCT recipi-
ents may be even more challenging, especially for
those innate and adaptive immune responses most
readily influenced by the microenvironment.
5. Age of the donors and recipients: the majority of
murine HSCT studies use primarily young adult
mice and only on rare occasions older mice will
be used. Older age in mice is known to alter APC
capacity, thymopoiesis and peripheral T cell recov-
ery, and sensitivity to radiation.
Previous reviews [1,2,7-11] have detailed these
phases of GVHD initiation and tissue destruction. I
will focus on recent advances in GVHD pathophysiol-
ogy and provide a perspective as to how these data suc-
ceeded or failed to be translated to the bedside. I will
also discuss potential preclinical leads that warrant
consideration for future clinical translation.
Priming of the Immune Response
The earliest phase of aGVHD is set into motion by
the damage caused by the underlying disease and exac-
erbated by conditioning regimens. It is noticeable that
IL-1 blockade [12] or protection of epithelial tissue
damage by infusion of keratinocyte growth factor,
although partially efficacious in some experimental
GVHD models [13,14], thus far have proved ineffec-
tive in preventing aGVHD in a randomized human
trial performed in matched sibling donors [15].
Because the mechanisms associated with (late onset)
aGVHD after reduced (eventually minimal) condi-
tioning have not been well elucidated, additional
studies are warranted that go back to the bench to de-
velop so-called ‘‘minitransplant’’ in the mouse setting
that may complement the aforementioned canine
investigations.T Cell Activation and Costimulation
The core of the graft-versus-host immune reaction
lies within the second step, in which donor T cells
proliferate and differentiate in response to host APCs
[16,17]. In humans, the incidence of aGVHD is
directly related to the degree of mismatch between
HLA determinants [18], mapped by high-resolution
DNA typing of HLA genes with polymerase chain
reaction-based techniques, largely replacing earlier
cellular methods. However, recipients of HLA-
identical grafts still can develop systemic aGVHD
due to genetic differences that lie outside the MHC
loci and that encode proteins referred to as minor his-
tocompatibility antigens (MiHA). Thus, there is
strong evidence for MiHA-mismatch-mediated
GVHD in humans [19-21]. However, although indi-
vidual human MiHA antigens associated with
GVHD have been identified, the relative contribution
of diverse MiHA and the existence (if any) of single,
dominant MiHA in humans. Donor and recipient
polymorphisms of cytokine genes ascribed to the cyto-
kine storm in rodents and humans also have been
implicated as risk factors for the disorder.
Amajor role forGVHDinitiation has been ascribed
to CD28/CTLA-4 (CD152):B7 interactions, which
consists of both a positive (CD28/B7) and an
inhibitory (CTLA-4:B7) pathway. Translating data on
costimulatory molecules for GVHD prevention into
the clinic turns out to be much more difficult. Data
on a limited number of patients suggest that
costimulatory blockade accomplished by adding
CTLA4-Ig to an in vitro mixed lymphocyte reaction
culture resulted in donor antihost hyporesponsive
T cells that supported relatively rapid T cell immune
recovery and a seemingly low propensity to cause
aGVHDwhen added to a haploidentical stem cell graft
[22,23]. More broadly directed in vitro methodologies
have been recently devised to depleted alloreactive
T cells, and such methodologies have been applied to
studies in a limited number of patients [24]. The new
CTLA4Ig derivative Abatacept, which preferentially
blocks CD28/B7 interactions, is highly efficient in the
treatment of rheumatoid arthritis and psoriasis and in
preventing acute solid organ graft rejection, has not
been tested to date for aGVHD prophylaxis [25].Acute GVHD and T Cell Subpopulations
In the clinic, quantification of the degree and lo-
cation of early T cell expansion is not readily possi-
ble given the limitations of current technology that
can be applied to HSCT recipients. Nonetheless,
clinical studies are planned to extrapolate in vivo ro-
dent data by transferring enriched memory T cells
rather than na€ıve T cells to the recipient at the
time of HSCT. It is unknown whether the expansion
of Treg will permit retention of as high a level of
Biol Blood Marrow Transplant 18:S17-S26, 2012 S23Biology of Acute GVHDsuppressor function as the CD41251 population
[26]. In HSCT human recipients, recent studies indi-
cate that the reduced aGVHD lethality seen despite
the infusion of high numbers of T cells contained
in a granulocyte-colony stimulating factor mobilized
peripheral blood stem cell graft is associated with in-
creased donor natural killer T cells [27,28]. Our data
indicate that Th17 cells in human GVHD Th17 cells
are not as numerous as in Crohn’s disease but that
the ratio of Th17 to Treg is associated with human
pathology [29].
T Cell Trafficking
How T cells are recruited into tissues could be
pivotal for understanding the stereotypical involve-
ment of skin, liver, and bowel in GVHD. Strategies
that influence T cell migration, particularly to
GVHD target organs, may offer promise for reducing
GVHD target organ specific injury, although the
redundancy of chemokines and their receptors may
hinder clinical efficacy in the context of GVHD pre-
vention or therapy. As such, targeting lymphocyte/in-
tegrin interaction may be a more promising way to
explore. Indeed, the research of targeting lymphocyte
trafficking has been taking into the clinic in diseases re-
lated to GVHD, such as rheumatoid arthritis and
colitis. For example Natalizumab, a humanized mono-
clonal antibody against alpha4 integrin, has been
tested in phase III clinical trials in Crohn’s disease
and beneficial results have been reported [30,31].
Effector Stage: T Cells and Others
After migration of alloreactive effector T cells to
the target tissues of GVHD, these cells can mediate
tissue destruction through both direct cytotoxic activ-
ity and the recruitment of other leukocytes. The con-
centration and timing of cytokine release into the
circulation and relevant target organs appear to be crit-
ical for GVHD. For example, IL-10 promotes Th2
and type 1 regulatory T cell responses, which can be
important in the induction of tolerance to allografts
(reviewed in [1]). Higher production of IL-10, as dem-
onstrated in human recipients with IL-10 production
polymorphism, is associated with reduced occurrence
and severity of GVHD [32]. In studies of transplant
patients, polymorphisms in the TNF-a gene of
HSCT recipients are associated with higher levels of
production of the cytokine and are correlated with
a higher incidence of severe aGVHD [33] (and review
in [34]), which suggests that, in humans, induction of
TNF-a from recipient cells may make an important
contribution to disease. Regardless of the source of
TNF-a, its importance in GVHD is borne out with
the demonstration that treatment of steroid-resistant
GVHD with a TNF-a blocker has shown efficacy,
especially against gastrointestinal disease, in somestudies [35-37] or when administrated for GVHD
prophylaxis [38]. Although preliminary studies by the
University of Michigan also suggested that an anti
TNF-a antibody (Etanercept) in addition to steroids
was superior to steroids alone as initial treatment for
aGVHD [36], a recent multicenter 4-arm BMT-
CTN randomized trial designed to identify the most
promising agent(s) for initial therapy for aGVHD
indicated that Etanercept was not most effective agent
to be combined with steroids for GVHD therapy [39].
In humans, the role of monocytes/macrophages in
effector phase not well established. GVHD effector
molecules other than TNF are not well established
and the pathogenicity of myeloid cells is not well
established.REFERENCES
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PROPHYLAXIS: LESSONS LEARNED
Corey Cutler, MD MPH FRCP(C)
Despite decades of research, and the central role
GVHD plays in clinical transplantation, there has
been a relative paucity of well-designed, randomized
trials in aGVHD prophylaxis. In fact, the most recent
series of very large randomized trials of pharmacologic
GVHD prophylaxis were published over a decade ago
[1,2]. Numerous candidate compounds have since
been tested in single and multicenter studies, but
only a few (such as mycophenolate mofetil [3] and an-
tithymocyte globulin [4]) have yet to be tested in Phase
III trials. Using the BMTCTN0402 study as an exam-
ple, this synopsis will review pitfalls in the implemen-
tation of Phase III trials in GVHD prophylaxis.Investment of Time
From trial concept to completion of accrual, BMT
CTN 0402 required 7 years. Added to this are 4 years
of preliminary Phase I and II trials [5-7] and the time
for data maturation, analysis, and dissemination. Dur-
ing this 12-year period the field of transplantation
biology and clinical science should not be static, and
there is a risk that novel concepts, trials, or even trial
results would eclipse this study, rendering the results
obsolete before they were ascertained. What options
are there to the lengthy time commitment of the Phase
III trial? One option is the randomized Phase II trial.
Phase II trials require smaller patient populations
and are generally monitored in a less rigorous fashion.
As opposed to single arm phase II studies, randomized
Phase II trials can test time-to-event endpoints (versus
timed static endpoints as in single arm Phase II trials)
and can study biomarkers in a rigorous fashion [8].
Most importantly, randomized Phase II studies actu-
ally test the hypothesis that the study intervention is
superior to a control, whereas single-arm Phase II
studies cannot. The randomized Phase II design has
now been used in stem cell transplantation as it allows
an accurate assessment of aGVHD risk in the patient
population being tested [9,10]. An alternative is to
perform smaller Phase III trials, using shorter,
nonsurvival endpoints, such as the incidence ofGVHD or disease relapse, rather than survival end-
points [11]. One final approach to minimize the time
required to complete a randomized trial is the use of
an adaptive randomization approach. The adaptive
treatment randomization strategy is useful only when
the endpoint being measured occurs soon after the in-
tervention, such as GVHD. It generally is not used in
large trials or in trials with long treatment duration,
because the randomization of future subjects depends
on the outcome of those preceding them. In fact, large
trials or trials with delayed endpoints using this design
may require longer to complete [12].
Clinical Trial Design—Rigidity versis Flexibility
A certain degree of homogeneity in clinical trial
design and implementation is required to ensure that
patients receive the study intervention as intended.
In BMT CTN 0402, it was required that sirolimus
levels be measured by high-performance liquid
chromatography-mass spectrometry (HPLC-MS)
technology, which is not available in all clinical chem-
istry laboratories. Newer ELISA technology had
recently been made available; however, levels of siroli-
mus using the commercial ELISA assays were noted to
overestimate levels measured by HPLC-MS due to in-
terference by sirolimus metabolites [13,14]. As a result,
participation by several potential clinical trial sites was
limited due to the inability to obtain sirolimus levels by
HPLC-MS in a timely manner necessary for clinical
care. To determine whether HPLC-MS methodology
was actually required, several groups simultaneously
measured sirolimus levels by HPLC-MS and ELISA
simultaneously. No significant trends or differences
in levels were noted, suggesting that this was an over-
cautious element in the trial design (L. Johnston,
Stanford, personal communication). Conversely, in
order to ensure that differences in opinion on condi-
tioning regimens would not limit clinical trial
participation, it was decided that both traditional mye-
loablative regimens (cyclophosphamide/total-body
irridiation and busulphan/cyclophosphamide) would
be allowed in BMT CTN 0402. It is notable that in
all prior Phase II trials leading up to BMT CTN
0402 only the Cyclophosphamide/total-body irridia-
tion regimen was used. The consequences of this deci-
sion were less benign, and the trial had to be halted
after 4 of the first 6 patients randomized to sirolimus
who were assigned a busulfan-based conditioning reg-
imen developed veno-occlusive disease [15]. This
observation also lead to the recognition of the weaker
association of sirolimus and veno-occlusive disease in
total-body irridiation-based transplantation.
Generalizability of Results
Because the conduct of large clinical trials is time
consuming, costly, and most importantly, requires
the investment of patient-subjects, it is hoped that the
S26 Biol Blood Marrow Transplant 18:S17-S26, 2012P. Reddy et al.results of a large clinical trial will either establish a new
care standard, or confirm the superiority of an existing
one. Whether the results of the clinical trial can be ap-
plied to similar, but not exactly the same, patient pop-
ulations that were included in the clinical trial always
remains to be seen. Inclusion criteria are designed to
ensure that the patient population is homogeneous
and to ensure that random events do not imbalance
treatment groups. However, if too restrictive, then
the results are not applicable to other patient groups.
BMT CTN 0402 was restricted to patients with
matched, sibling donors who had myeloid malignan-
cies or acute lymphoblastic leukemia. Are the forth-
coming results applicable to patients with matched
unrelated donors? With lymphoid malignancies? If
the results are interpreted too narrowly, then we are
faced potentially with 2 standards for similar but not
identical populations. If interpreted too broadly, then
patients may be mistreated. Repeating a Phase III trial
of this size will require several additional years of study,
which may not be in the best interest of all patients.
Despite these and other stumbling blocks, the ran-
domized Phase III trial remains the ‘‘standard of care’’
in clinical transplantationandmodernmedicine.Under-
standing these, and other issues in Phase III trial design,
will lead to more informative clinical trials in the future.ACKNOWLEDGMENTS
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